My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Medifam
Print version ISSN 1131-5768
Abstract
CALVO ROMERO, J. Mª. and LIMA RODRIGUEZ, E. Mª.. Repaglinide, a new oral antidiabetic agent . Medifam [online]. 2001, vol.11, n.6, pp.27-30. ISSN 1131-5768.
The arsenal of oral agents with usefulness in the treatment of type 2 diabetes mellitus has been extended in the last few years. Repaglinide is the first of a new class of oral antidiabetic agents that are benzoic acid derivatives, which is a nonsulfonylurea insulin secretagogue. Repaglinide improves the prandial glucose regulation, restoring the diminished and delayed insulin secretion related with the meals in type 2 diabetic patients. When used as monotherapy, the decreases in fasting plasma glucose and glycosylated hemoglobin is similar to those observed with sulfonylureas or metformin.
Keywords : Repaglinide; Oral antidiabetic agents; Type 2 diabetes mellitus.